A 47-year-old with a father who had an MI at 58 lands on your preventive cardiology site at 10pm. He has read Outlive, knows ApoB matters more than LDL-C, wants Lp(a) tested once, and is debating whether a CAC score makes sense at his age. Your site has a screening page, a lipid management page, a fees PDF, and a blog post on Lp(a). He bounces, or books an Attia-style consult elsewhere because the path was too long.

SleekAI maps your service custom post type, lipid panel postmeta, provider bios, and imaging schedules into resolvable variables. A visitor types 'should I get a CAC at 47 with family history and what does the consult cost' and the bot pulls the consult fee, the CAC service record, and the family-history guidance from your protocol postmeta. It quotes the $385 new-patient consult, the $185 CAC scan, explains your typical recommendation (CAC at 40-45 with family history), and offers a slot with the preventive cardiologist.

Generic chatbots can't do this. They can't read wp_postmeta for your clinic's ApoB target or CAC screening age, can't filter providers by board certification, and don't know that a CAC of 100 in a 40-year-old is high-risk while in a 70-year-old it is average. They send the patient a brochure. SleekAI treats your cardiology content as first-class data and respects the difference between ApoB-targeted, LDL-C-targeted, and Lp(a)-aware risk frameworks.

Preventive cardiology patients arrive informed. They have read Outlive, listened to The Drive, and follow lipidologists on Twitter. They know ApoB matters more than LDL-C, that Lp(a) is genetic and measured once, and that a CAC score in a 45-year-old means something different than in a 70-year-old.

They want concrete answers before booking a $385 consult. A bot that can quote your advanced lipid panel cost, explain your ApoB target, recommend the right screening for a patient with family history, and book a Wednesday consult collapses the path from research to revenue. Front-desk staff stops fielding the same six panel comparison questions, which frees them for prior authorization work on PCSK9 inhibitors and patient lipid follow-ups.

The bot also surfaces underused services. A patient asking about a statin learns that you also do CGM-based metabolic workups for insulin-resistance contribution to ASCVD risk, which expands the consult scope. Sub-specialty routing prevents the mismatch where a women's cardiology case ends up with a generalist.

Conversation logs reveal which screenings prospects ask about most often, which informs the content roadmap. Over time the data identifies which protocols need clearer pricing pages and which providers patients request by name.